SOURCE: National Stem Cell Holding, Inc.

June 18, 2008 10:14 ET

OTC Financial Network Issues Corporate Profile on National Stem Cell Holding, Inc.

MOUNTAINSIDE, NJ--(Marketwire - June 18, 2008) - National Stem Cell Holding, Inc. (PINKSHEETS: NHGI) today announced that OTC Financial Network (OTCFN), a division of National Financial Communications Corp., has issued a Corporate Facts Report on the Company. The report highlights the Company's transition from the R&D stage to the commercialization stage. Further, the report highlights some of its upcoming products, including, but not limited to: unique products that combine cosmetics and pharmaceuticals (cosmoceuticals) that will target this $8.2 billion industry; a platform technology, which enhances the growth and expansion of cells that will target the $2 billion global laboratory market; and cell therapeutics for diabetes and cardiac disease. Interested parties can download the report at or call 781-444-6100 ext. 625 for reprints.

Publisher of the OTCFN report, Geoffrey Eiten, said, "National Stem Cell is an innovative biotech company that is emerging out of its research and development stage and commencing the commercialization of patented and proprietary technologies based on cutting-edge regenerative cell research in order to enhance its shareholders' value. Multiple cosmoceutical products that target the huge anti-aging skin care industry will be marketed to plastic surgeons, dermatologists and health care professionals beginning in the fourth quarter of 2008."

"Cosmoceuticals, together with a number of cell therapeutics in the pipeline, provide National Stem Cell with the opportunity to capitalize on the tremendous medicinal and life-saving opportunities in the global regenerative cell market for the benefit of its early shareholders," concluded Eiten.

About OTC Financial Network

OTC Financial Network (OTCFN) has carved its niche as the nation's leading small/micro-cap investor relations and financial communications firm. OTCFN provides full-service investor relations, consulting services and customized marketing campaigns designed to maximize investor awareness for small/micro-cap publicly traded companies. Since its inception in 1992, OTCFN has represented over 500 clients. To view a current client list or for more information, visit OTCFN is a division of National Financial Communications Corp. ( based in Needham, MA.

Disclaimer: OTC Financial Network (OTCFN) serves as special advisor to the featured Company and has received fees for services, including three-hundred thousand shares of common stock for payment of a monthly retainer of five thousand dollars and other expenses, plus the option to purchase a total of one-million shares of common stock at an exercise price of seventy-five cents per share for two-hundred fifty thousand shares, one dollar and twenty-five cents for two-hundred fifty thousand shares and two dollars for five hundred thousand shares, plus expenses. This is not an offer to buy or sell securities. Information or opinions in this release are presented solely for informative purposes, and are not intended nor should they be construed as investment advice. A full disclaimer can be found online by visiting

About National Stem Cell Holding, Inc.

National Stem Cell Holding, Inc. is a biotechnology company focused on the development and commercialization of cell therapeutics, primarily used to treat diabetes and cardiac disease. National Stem Cell also provides cell and reproductive tissue laboratory services, including processing and banking, and owns multiple, patented technologies that are used to create a proprietary line of products. Through its ownership of the skin care company, ProteoDerm Inc., National Stem Cell plans to launch its first line of cosmetic pharmaceuticals in Q4 2008. For more information on the Company, visit or

"Safe Harbor Statement"

Under The Private Securities Litigation Reform Act of 1995: The statements in the press release that relate to the company's expectations with regard to the future impact on the company's results from new products and products in development are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The results anticipated by any or all of these forward-looking statements may not occur. The Company undertakes no obligation to publicly release the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof, or to reflect the occurrence of unanticipated events or changes in the Company's plans or expectations.

Contact Information